Skip to content

Ultrasound prediction of axillary response to neoadjuvant chemotherapy in patients with node-positive breast cancer

Ultrasound prediction of axillary response to neoadjuvant chemotherapy in patients with node-positive breast cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053240
Enrollment
Unknown
Registered
2021-11-17
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Gold Standard:Axillary lymph node pathology results
Index test:Ultrasound&#32
(Number,&#32
hilum
&#32
and&#32
of&#32
tumor).

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who received surgical treatment after NAC; 2. Patients who received MRI and US before and after NAC; 3. Breast cancer patients with positive clinical lymph nodes (pathologically confirmed or clinically suspected axillary lymph node metastasis).

Exclusion criteria

Exclusion criteria: 1. Distant metastasis occurs for the first time; 2. History of breast cancer; 3. Patients treated by other institutions.

Design outcomes

Primary

MeasureTime frame
lymph node cortical thickness;number of lymph nodes;reduction ratio in size;lymph hilus;accuracy, specificity, sensitivity, AUC of ROC;

Secondary

MeasureTime frame
size of primary cancer;number of primary lesions;

Countries

China

Contacts

Public ContactXu Jinshun

West China Hospital of Sichuan University

xujinshun@wchscu.cn+86 18708491127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026